Skip to content
DAEWOONG THERAPEUTICS

CLOPAM® · For obesity & MASH peptide developers

Your peptide.On a patch.Once a week.

In the most crowded race in medicine, delivery is where a GLP-1-class peptide can still stand apart. CLOPAM turns a weekly injection into a weekly microneedle patch.
Test your peptide See why
Bioavailability vs SC injection, GLP-1 peptide in humans
~80%Bioavailability vs SC injection, GLP-1 peptide in humans
The same weekly cadence as the injection
1×/wkThe same weekly cadence as the injection
Needles to see, fear or dispose of
0Needles to see, fear or dispose of

01 — The race

The most crowded race in medicine.

When everyone has a GLP-1, the molecule stops being the difference.

  1. 01

    Everyone is in

    Global pharma and biotech are pouring programs into GLP-1-class peptides — single, dual and triple agonists, weekly and longer-acting — all chasing the same patients.

  2. 02

    Molecules converge

    As efficacy and safety converge across the class, the next program has to win on something patients feel every week: how it is taken.

  3. 03

    MASH raises the stakes

    GLP-1-based therapies are moving from obesity into MASH and other metabolic disease, where treatment is long-term and staying on therapy decides the outcome.

02 — The adherence gap

Most people don't stay on the injection.

Weekly injections work — for the patients who keep taking them.

Why weekly injections get dropped

  • Needle fear and injection fatigue over months of weekly doses
  • Pens to store, carry and dispose of as sharps
  • Treatment that feels medical, every single week

Weight comes back when treatment stops. A form patients are willing to keep using is worth as much as the molecule.

03 — Once a week, on a patch

Once a week, on a patch.

A microneedle patch can keep the weekly regimen patients and prescribers already know.

  1. 01

    High drug loading

    CLOPAM packs an unusually high peptide load into each patch — enough to carry a full weekly dose.

  2. 02

    Aero-pressure tip concentration

    Our patented aero-pressure manufacturing drives the drug into the needle tips, so it is deposited deep in the skin for high systemic absorption.

  3. 03

    ~80% of SC bioavailability

    In human pilot PK studies with a GLP-1 peptide, the patch reached about 80% of the bioavailability of the SC injection — enough to keep the same once-a-week schedule.

Weekly SC injection

  1. Monneedle
  2. Tue
  3. Wed
  4. Thu
  5. Fri
  6. Sat
  7. Sun

Weekly CLOPAM patch

  1. Monpatch
  2. Tue
  3. Wed
  4. Thu
  5. Fri
  6. Sat
  7. Sun

Same once-a-week rhythm. One less needle every week.

04 — What else it brings

Everything else a patch brings.

  • No needle to fear

    Microneedles dissolve in the skin; patients never see or handle a needle.

  • Self-applied at home

    A pressure-activated applicator confirms each application with an audible click.

  • No sharps waste

    The needles dissolve, so there is nothing sharp to store, carry or dispose of.

  • Gentle on the skin

    Almost no skin irritation in human pilot studies.

  • Discreet and portable

    A small patch in hermetic packaging, easy to carry when travelling.

  • A new presentation

    A weekly patch differentiates a new peptide or extends the life cycle of a marketed one.

  • Made at scale, aseptically

    The world's first fully aseptic microneedle patch plant runs in Hyangnam, with a commercial-scale plant to follow.

  • Already in obesity

    A top-tier global obesity & endocrinology company is developing a peptide on CLOPAM with us.

Make your peptide stand out.

Send us your peptide under an MTA. We'll come back with patch feasibility data on your own molecule.

Test your peptide

~80% is relative bioavailability against SC injection in human pilot PK studies with a GLP-1 peptide; results vary by molecule and are confirmed in development. Persistence figures are from the cited real-world studies.